According to the PDB sample hospital database, the overall sales in China sample hospitals reached RMB 222.3 billion in 2017, wherein, there were 45 varieties with sales exceeding RMB 1 billion, and their total sales reached RMB 66.148 billion, accounting for about 29.76% of the overall sales.
|
Pharmaceutical product name
|
Sales in sample hospitals (RMB 100 million)
|
|
Sodium chloride
|
32.12
|
|
Human albumin
|
32.02
|
|
Clopidogrel
|
23.95
|
|
Atorvastatin
|
22.09
|
|
Paclitaxel
|
20.37
|
|
Entecavir
|
19.96
|
|
Gangliosides
|
19.70
|
|
Meropenem
|
18.01
|
|
Alprostadil
|
17.84
|
|
Pantoprazole
|
17.73
|
|
Oxiracetam
|
17.43
|
|
Phosphocreatine
|
17.04
|
|
Dezocine
|
16.34
|
|
Lansoprazole
|
15.53
|
|
Voriconazole
|
15.07
|
|
Moxifloxacin
|
14.50
|
|
Pemetrexed
|
14.25
|
|
Human immunoglobulin
|
14.08
|
|
Piperacillin/tazobactam
|
14.07
|
|
Compound amino acid
|
13.72
|
|
Cefoperazone-sulbactam
|
13.18
|
|
Docetaxel
|
13.12
|
|
Omeprazole
|
13.02
|
|
Propofol
|
12.75
|
|
Thymosin α-1
|
12.46
|
|
Mouse nerve growth factor
|
12.24
|
|
Esomeprazole
|
12.16
|
|
Budesonide
|
11.96
|
|
Tegafur-gimeracil-oteracil potassium
|
11.71
|
|
Levofloxacin
|
11.69
|
|
Flurbiprofen
|
11.55
|
|
Edaravone
|
11.17
|
|
Rosuvastatin
|
11.03
|
|
Tacrolimus
|
10.91
|
|
Acarbose
|
10.90
|
|
Deproteinized calf blood extract
|
10.87
|
|
Hemocoagulase
|
10.77
|
|
Rituximab
|
10.75
|
|
Butylphthalide
|
10.70
|
|
Coenzyme complex
|
10.63
|
|
Thymopentin
|
10.61
|
|
Rabeprazole
|
10.55
|
|
Ambroxol
|
10.42
|
|
Oxaliplatin
|
10.41
|
|
Ribonucleic acid
|
10.10
|
From the perspective of variety category, the pharmaceutical product categories of the Top 5 in the above list are separately anti-infective drugs, blood and hematopoietic system drugs, cardiovascular drugs, nervous system drugs, and oncology drugs. The above 5 categories have been keeping the similar sales rankings in the past 5 years.
|
類型分布
|
Category distribution
|
|
抗感染類
|
Anti-infective drugs
|
|
血管和造血系統(tǒng)用藥
|
Blood and hematopoietic system drugs
|
|
心腦血管系統(tǒng)用藥
|
Cardiovascular drugs
|
|
神經(jīng)系統(tǒng)用藥
|
Nervous system drugs
|
|
抗腫瘤藥
|
Oncology drugs
|
|
消化系統(tǒng)用藥
|
Digestive system drugs
|
|
免疫調(diào)節(jié)劑
|
Immunomodulators
|
|
內(nèi)分泌及代謝調(diào)節(jié)用藥
|
Endocrine and metabolic regulation drugs
|
|
呼吸系統(tǒng)用藥
|
Respiratory system drugs
|
|
其他
|
Others
|
Varieties with significant changes in growth
The growth of the 45 varieties with sales in sample hospitals exceeding RMB 1 billion formed a distinct contrast. 12 varieties had rapid growth in market size (growth>10%), wherein, esomeprazole, flurbiprofen, and dezocine achieved growth of 10%, ranking the top 3 in the growth rankings; 10 varieties had rapid shrinkage in market size (growth<-10%), wherein, thymopentin had the most evident shrinkage, with 2017 sales down by 27.75% year on year. Overall, different varieties had clear differentiation, and the market size was rapidly changing.
|
Variety name
|
Growth
|
|
Esomeprazole
|
22.45%
|
|
Flurbiprofen
|
20.91%
|
|
Dezocine
|
20.72%
|
|
Tacrolimus
|
14.82%
|
|
Butylphthalide
|
14.52%
|
|
Rabeprazole
|
14.39%
|
|
Rituximab
|
14.04%
|
|
Cefoperazone-sulbactam
|
13.90%
|
|
Moxifloxacin
|
12.46%
|
|
Piperacillin/tazobactam
|
11.49%
|
|
Voriconazole
|
11.47%
|
|
Budesonide
|
11.30%
|
|
Thymopentin
|
-27.75%
|
|
Gangliosides
|
-19.36%
|
|
Lansoprazole
|
-18.19%
|
|
Coenzyme complex
|
-17.59%
|
|
Oxiracetam
|
-15.53%
|
|
Deproteinized calf blood extract
|
-15.29%
|
|
Alprostadil
|
-14.49%
|
|
Mouse nerve growth factor
|
-14.12%
|
|
Ambroxol
|
-13.53%
|
|
Phosphocreatine
|
-10.89%
|
|
增速變化顯著品種
|
Varieties with Significant Changes in Growth
|
|
胸腺五肽
|
Thymopentin
|
|
神經(jīng)節(jié)苷脂
|
Gangliosides
|
|
蘭索拉唑
|
Lansoprazole
|
|
復(fù)合輔酶
|
Coenzyme complex
|
|
奧拉西坦
|
Oxiracetam
|
|
小牛去血蛋白提取物
|
Deproteinized calf blood extract
|
|
前列地爾
|
Alprostadil
|
|
鼠神經(jīng)生長因子
|
Mouse nerve growth factor
|
|
氨溴索
|
Ambroxol
|
|
磷酸肌酸
|
Phosphocreatine
|
|
布地奈德
|
Budesonide
|
|
伏立康唑
|
Voriconazole
|
|
哌拉西林他唑巴坦
|
Piperacillin/tazobactam
|
|
莫西沙星
|
Moxifloxacin
|
|
頭孢哌酮舒巴坦
|
Cefoperazone-sulbactam
|
|
利妥昔單抗
|
Rituximab
|
|
雷貝拉唑
|
Rabeprazole
|
|
丁苯酞
|
Butylphthalide
|
|
他克莫司
|
Tacrolimus
|
|
地佐辛
|
Dezocine
|
|
氟比洛芬
|
Flurbiprofen
|
|
埃索美拉唑
|
Esomeprazole
|
Exclusive varieties
There were 4 varieties sold exclusively on the Chinese market among the 45 varieties with sales in sample hospitals exceeding RMB 1 billion. See the following table. Wherein, the market size of dezocine of Yangtze River Pharmaceutical, rituximab of Roche, and butylphthalide of CSPC significantly grew in 2017, while the sales of coenzyme complex of SL Pharmaceutical shrank by 17.59%, showing that there was also differentiation among the exclusive varieties.
|
Varieties Sold Exclusively on the Chinese Market
|
|
Variety name
|
Sales in sample hospitals (RMB 100 million)
|
Manufacturer
|
Growth
|
|
Dezocine
|
16.34
|
Yangtze River Pharmaceutical
|
20.72%
|
|
Rituximab
|
10.75
|
Roche
|
14.04%
|
|
Butylphthalide
|
10.70
|
CSPC
|
14.52%
|
|
Coenzyme complex
|
10.63
|
SL Pharmaceutical
|
-17.59%
|
Varieties clearly dominated by single Chinese manufacturers
With the market shares of manufacturers of corresponding varieties estimated according to the data of sales in China sample hospitals, the list of varieties clearly dominated (market share>40%) by single Chinese manufacturers is as shown below, including a total of 11 Chinese pharmaceutical enterprises, wherein, Jilin Aodong Medicine Industry had the highest market share in ribonucleic acid.
|
Variety name
|
Manufacturer
|
Estimated market share
|
|
Ribonucleic acid
|
Jilin Aodong
|
99.7%
|
|
Flurbiprofen
|
Beijing Tide
|
98.3%
|
|
Deproteinized calf blood extract
|
Jinzhou Ahon
|
75.5%
|
|
Paclitaxel
|
Luye Pharma
|
63.6%
|
|
Gangliosides
|
Qilu Pharmaceutical
|
62.2%
|
|
Edaravone
|
Simcere Dongyuan
|
52.9%
|
|
Tegafur-gimeracil-oteracil potassium
|
New Time Pharmaceutical
|
51.1%
|
|
Hemocoagulase
|
Consun Pharmaceutical
|
49.4%
|
|
Entecavir
|
Chia Tai Tianqing
|
44.0%
|
|
Docetaxel
|
Hengrui Medicine
|
43.0%
|
|
Omeprazole
|
Aosaikang
|
43.0%
|
About the author: Xiaoyaowan, a pharmaceutical industry practitioner, "word porter" in the era of we-media, focusing on the climate changes in the pharmaceutical circle.
Register as Visitor to CPhI China 2018!
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
